1. Current challenges and future perspectives in oral absorption research : an opinion of the UNGAP network
- Author
-
Saskia N. de Wildt, Patrick Augustijns, Anette Müllertz, Mark McAllister, Cordula Stillhart, Brendan T. Griffin, James Butler, Kateřina Valentová, Andreas Bernkop-Schnürch, Nigel Davies, Caitriona M. O'Driscoll, Christos Reppas, Hannah Batchelor, Clive G. Wilson, Filippos Kesisoglou, Mirko Koziolek, Maria Vertzoni, Alan R. Mackie, Bertil Abrahamsson, Christopher J.H. Porter, Kiyohiko Sugano, Jadwiga Paszkowska, Zahari Vinarov, Didier Dupont, Martin Kuentz, Nikoletta Fotaki, Janneke Keemink, Jens Ceulemans, Petr Pavek, Gøril Eide Flaten, Elena Toader, Per Artursson, Vincent Jannin, Philippe Berben, Neil Parrott, Antonio J. Meléndez-Martínez, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Department of Chemical and Pharmaceutical Engineering, Medical University of Sofia [Bulgarie], Oral Product Development, Pharmaceutical Technology & Development, Operations, ASTRAZENECA R/D GLOBAL SAFETY ASSESSMENT SODERTALJE SWE, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Department of Pharmacy, Uppsala University, Uppsala University, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UCB Pharma S.A.[Braine-l'Alleud], Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, GlaxoSmithKline, Glaxo Smith Kline, Janssen Pharmaceutica N.V. [Beerse, Belgium], AstraZeneca, Gothenburg, Sweden, Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Department of Pharmacy, University of Tromsø (UiT), Department of Pharmacy and Pharmacology, University of Bath [Bath], School of Pharmacy, University College Cork (UCC), Lonza Pharma & Biotech, Lonza AG, Valais Works, CH-3930 Visp, Switzerland, Partenaires INRAE-Partenaires INRAE, Pharmaceutical Sciences, Merck & Co. Inc., Merck Research laboratories, Merck & Co. Inc-Merck & Co. Inc, AbbVie Deutschland GmbH & Co KG, Abbott GmbH & Co KG, Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland (HES-SO), School of Food Science & Nutrition, University of Leeds, Food Colour & Quality Laboratory, Area of Nutrition & Food Science, Universidad de Sevilla, Drug Product Design, Pfizer PGRD, Pfizer-Pfizer, University of Copenhagen = Københavns Universitet (KU), F. Hoffmann-La Roche Ltd. [Basel, Switzerland], Physiolution Polska Sp. Z o.o., Wroclaw, Poland, Faculty of Pharmacy, Charles University Faculty of Medicine and Faculty Hospital in Hradec Kralove, Monash Institute of Pharmaceutical Sciences, Department of Drug Delivery, Disposition and Dynamics, Faculty of Pharmacy and Pharmaceutical Science, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia, Department of Pharmaceutical Technology, National and Kapodistrian University of Athens, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Faculty of Medicine, University of Medicine and Pharmacy of Iasi, Romania, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic, and Department of Pharmacology and Toxicology, Radboud University Medical Center
- Subjects
VIVO PERFORMANCE ,Administration, Oral ,Pharmaceutical Science ,02 engineering and technology ,Absorption (psychology) ,Pharmaceutical Sciences ,INTESTINAL PERMEABILITY ,Medicine ,FED STATE ,Food-drug interactions ,0303 health sciences ,Specific patient populations ,BIOPHARMACEUTICS TOOLS PROJECT ,021001 nanoscience & nanotechnology ,In vitro tools ,3. Good health ,Pharmaceutical Preparations ,Colonic absorption ,BIORELEVANT DISSOLUTION ,Engineering ethics ,0210 nano-technology ,Amorphous solid dispersions ,Advanced formulations ,Drug Compounding ,DOSAGE FORMS ,RS ,03 medical and health sciences ,Lipid-based formulations ,Animals ,Humans ,Regional differences ,Computer Simulation ,030304 developmental biology ,PHARMACOKINETIC PBPK ,DRUG-DELIVERY SYSTEMS ,PBPK modeling ,IN-VITRO MODELS ,business.industry ,VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728 ,Farmaceutiska vetenskaper ,Gastrointestinal Tract ,Intestinal Absorption ,LIPID-BASED FORMULATIONS ,VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728 ,Microbiome ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,Oral retinoid - Abstract
Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations, (2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions. The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption, the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified controversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to create a roadmap for the future of oral drug absorption research.(c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
- Published
- 2021